The promise of autologous and allogeneic cellular therapies in the clinical trials of autism spectrum disorder

Tweetable abstractSummary of the current trends and outcomes of clinical trials conducted using different autologous and allogeneic cellular approaches to investigate cellular therapies' use, safety and efficacy in treating autism spectrum disorder. Autism spectrum disorder (ASD) is a consortium of developmental conditions. As scientists have not yet identified the exact underlying cause for these disorders, it is not easy to narrow down a singular therapy to propose a reliable cure. The preponderance of research suggests that stem-cell therapy improves aspects of outcome measure scales in patients with ASD; therefore, future studies should give us more confidence in the results. This overview considers the data that have emerged from the small set of published trials conducted using different approaches in stem-cell therapy for ASD, evaluates their results and proposes additional steps that could be taken if this field of endeavor is to be pursued further.

Automated summary

This article summarizes the current trends and outcomes of clinical trials using autologous and allogeneic cellular approaches to investigate the use of cellular therapies in treating autism spectrum disorder (ASD). Stem-cell therapy has shown improvements in outcome measures for patients with ASD, but more research is needed to confirm these results. The article evaluates data from published trials and proposes further steps for pursuing this field of research.